Sera Prognostics, Inc. (NASDAQ:SERA) Insider Sells $204,732.90 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) insider John J. Boniface sold 21,438 shares of the firm’s stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $9.55, for a total transaction of $204,732.90. Following the transaction, the insider now directly owns 143,524 shares in the company, valued at approximately $1,370,654.20. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Sera Prognostics Stock Performance

NASDAQ:SERA opened at $9.46 on Thursday. Sera Prognostics, Inc. has a fifty-two week low of $1.52 and a fifty-two week high of $10.44. The company’s 50-day simple moving average is $8.40 and its 200-day simple moving average is $5.00.

Institutional Trading of Sera Prognostics

Several institutional investors and hedge funds have recently bought and sold shares of SERA. Frontier Wealth Management LLC acquired a new stake in Sera Prognostics during the 1st quarter valued at approximately $30,000. Susquehanna International Group LLP acquired a new stake in shares of Sera Prognostics in the first quarter valued at about $39,000. Goldman Sachs Group Inc. acquired a new stake in shares of Sera Prognostics in the first quarter valued at about $41,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of Sera Prognostics in the first quarter valued at about $46,000. Finally, Bank of New York Mellon Corp acquired a new stake in Sera Prognostics during the first quarter worth about $50,000. 54.64% of the stock is currently owned by institutional investors and hedge funds.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.